SEC Form 4 · accession 0001214659-26-008663
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Barber
Officer — President and CEO
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 1:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001398733
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 15, 2026 | S | 4,631 | $4.0344 | D | 630,943 | D | |
| Common StockF2 | Jul 16, 2026 | S | 20,369 | $4.0016 | D | 610,574 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction involves sale transactions from $4.00 to $4.04 per share. The weighted average price per share was $4.0344. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.
- F2The reported transaction involves sale transactions from $4.00 to $4.01 per share. The weighted average price per share was $4.00016. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.